{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"4"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG001","value":"99"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG001","value":"18"}]}],"title":"Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG001","value":"1"}]}],"title":"Early death"},{"categories":[{"measurements":[{"groupId":"OG001","value":"11"}]}],"title":"Not evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"For patients that received preoperative radiotherapy, the tumor response was assessed using RECIST 1.1. Response criteria were essentially based on a set of measurable lesions identified at baseline as target lesions, and followed at the end of the radiotherapy. Response was not the primary endpoint, so a confirmatory CT-scan was not mandatory.","groups":[{"description":"En-bloc resection of surrounding tissues and organs when located within 1 to 2 cm from the surface tumor, even when not infiltrated.\n\ntherapeutic conventional surgery","id":"OG000","title":"Surgery Alone"},{"description":"3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions\n\ntherapeutic conventional surgery\n\n3-dimensional conformal radiation therapy","id":"OG001","title":"Preoperative Radiotherapy Followed by En-bloc Surgery"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Tumor response using RECIST 1.1 was only assessed for patients receiving preoperative radiotherapy.","reportingStatus":"POSTED","timeFrame":"Two weeks after completion of Pre-operative Radiotherapy, before Surgery","title":"Tumor Response to Preoperative Radiotherapy","type":"SECONDARY","unitOfMeasure":"Participants"}